Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-308-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.40 million
Profitability
Miscellaneous
Employees116
Next Earnings Date3/26/2019 (Estimated)
OptionableOptionable
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.18. Kadmon had a negative return on equity of 192.20% and a negative net margin of 3,848.01%. View Kadmon's Earnings History.
When is Kadmon's next earnings date?
What price target have analysts set for KDMN?
3 brokers have issued 1 year price targets for Kadmon's stock. Their predictions range from $2.77 to $25.00. On average, they expect Kadmon's share price to reach $10.2233 in the next twelve months. This suggests a possible upside of 267.7% from the stock's current price. View Analyst Price Targets for Kadmon.
What is the consensus analysts' recommendation for Kadmon?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.
Has Kadmon been receiving favorable news coverage?
News articles about KDMN stock have trended somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kadmon earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Innoviva (INVA), Aimmune Therapeutics (AIMT), Gossamer Bio (GOSS), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Cambrex (CBM), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), TherapeuticsMD (TXMD), Innovus Pharmaceuticals (INNV), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM) and Rhythm Pharmaceuticals (RYTM).
What other stocks do shareholders of Kadmon own?
Who are Kadmon's key executives?
Kadmon's management team includes the folowing people:
- Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
- Mr. Steven Meehan, Exec. VP & CFO (Age 54)
- Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
- Ms. Cynthia L. Schwalm, Director (Age 59)
- Mr. Kyle Carver, Controller & Principal Accounting Officer
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Who are Kadmon's major shareholders?
Kadmon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.08%), Puissance Capital Management LP (3.98%), Telemetry Investments L.L.C. (2.61%), Sofinnova Investments Inc. (1.46%), Geode Capital Management LLC (0.97%) and Geode Capital Management LLC (0.97%). Company insiders that own Kadmon stock include Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Which institutional investors are selling Kadmon stock?
KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., AE Wealth Management LLC, Asymmetry Capital Management L.P., MetLife Investment Advisors LLC and Old West Investment Management LLC. View Insider Buying and Selling for Kadmon.
Which institutional investors are buying Kadmon stock?
KDMN stock was bought by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., Puissance Capital Management LP, Millennium Management LLC, 683 Capital Management LLC, Fosun International Ltd, Virtus ETF Advisers LLC, BlackRock Inc. and GSA Capital Partners LLP. Company insiders that have bought Kadmon stock in the last two years include Eugene Bauer, Harlan Waksal and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $2.78.
How big of a company is Kadmon?
Kadmon has a market capitalization of $352.81 million and generates $1.40 million in revenue each year. The company earns $-54,250,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 116 workers across the globe.
What is Kadmon's official website?
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (NYSE KDMN)
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
